14 Dicembre 202014 Dicembre 2020The Board of Directors of Vera Salus Ricerca has voted in favour of the incorporation of FlavOncology in Switzerland with a dedicated, strong executive team comprising a mix of local entrepreneurs and key figures from the company’s shareholders.
7 Dicembre 20207 Dicembre 2020Vera Salus Ricerca has successfully completed a 1-year training at BioArk (Switzerland) aimed at polishing the business developmental plans of FlavOncology, its proprietary drug platform for the cure of cancer patients.